Clinical trials: Acute Myeloid Leukemia Refractory
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT07012044
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 15 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
AML, Acute Myeloid Leukemia
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid…
- Conditions
- AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- CertainT-1 (NCT06834282)
- Testing
- CER-1236, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- CERo Therapeutics Holdings, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03969446
- Testing
- Decitabine, Pembrolizumab, Venetoclax
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05263284
- Testing
- 8-Chloroadenosine, Venetoclax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back after a…
- Conditions
- Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT06454409
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML)
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors…
- Conditions
- Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute Myeloid Leukemia)
- Trial name
- NCT07347418
- Testing
- CD64 CAR T Cells
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Colorado, Denver
Leukemia, Acute Leukemia
A Study of Revumenib and Mezigdomide in People With Leukemia
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
- Conditions
- Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT07356154
- Testing
- Revumenib, Mezigdomide
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to…
- Conditions
- Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Trial name
- NCT03816319
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703…
- Conditions
- Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
- Trial name
- NCT06846606
- Testing
- AUTX-703
- Where
- 9 sites in United States
- Volunteers
- 69 people
- Sponsor
- Auron Therapeutics, Inc.
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of entrectinib when given with ASTX727 in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or that does not respond to treatment…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05396859
- Testing
- Decitabine and Cedazuridine, Entrectinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- OHSU Knight Cancer Institute
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia
This is a single-arm, single-center clinical study to assess the efficacy and safety of Mitoxantrone Hydrochloride Liposome combined with cladribine and sotoraclib in patients with relapsed/refractory acute myeloid leukemia…
- Trial name
- NCT07874737
- Testing
- Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to…
- Trial name
- NCT05222984
- Testing
- Decitabine, Navitoclax, Venetoclax
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory…
- Trial name
- NCT07355335
- Testing
- Ziftomenib, Mezigdomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic…
- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT07582172
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center